Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia

Pediatrics

Volumn 131, Issue 4, 2013, Pages 716-723

  Slaughter, Jonathan L ^a,b   Stenger, Michael R ^a   Reagan, Patricia B ^c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Bronchopulmonary dysplasia; Comparative effectiveness; Diuretics; Drug utilization; Patient centered outcomes; Pharmacoepidemiology; Practice variation; Prematurity

Indexed keywords

ACETAZOLAMIDE; BUMETANIDE; CHLOROTHIAZIDE; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METOLAZONE; SPIRONOLACTONE;

ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; COHORT ANALYSIS; COMORBIDITY; DIURETIC THERAPY; DRUG UTILIZATION; FEMALE; GESTATIONAL AGE; HUMAN; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NEWBORN; PEDIATRIC HOSPITAL; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES;

BRONCHOPULMONARY DYSPLASIA; CHLOROTHIAZIDE; COHORT STUDIES; DATABASES, FACTUAL; DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION; FEMALE; FUROSEMIDE; HOSPITALS, PEDIATRIC; HUMANS; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84875999225     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-1835     Document Type: Article

References (24)

1. Kao LC, Warburton D, Sargent CW, Platzker ACG, Keens TG. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. J Pediatr. 1983;103(4):624-629
2. Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011; (9): CD001453
3. Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011; (9):CD001817
4. Stewart AL, Brion LP. Routine use of diuretics in very-low birth-weight infants in the absence of supporting evidence. J Perinatol. 2011;31(10):633-634
5. Walsh MC, Szefler S, Davis J, et al. Summary proceedings from the bronchopul-monary dysplasia group. Pediatrics. 2006; 117(3 pt 2 suppl 1):S52-S56
6. Segar JL. Neonatal diuretic therapy: furo-semide, thiazides, and spironolactone. Clin Perinatol. 2012;39(1):209-220
7. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117(6): 1979-1987
8. Lindner U, Hilgendorff A, Frey G, Gortner L. Drug utilisation in very preterm infants: any changes during the past decade? Klin Padiatr. 2008;220(4):238-242
9. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163(7):1723-1729
10. Ehrenkranz RA, Walsh MC, Vohr BR, et al; National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of broncho-pulmonary dysplasia. Pediatrics. 2005;116 (6):1353-1360
11. Bland RD, McMillan DD, Bressack MA. Decreased pulmonary transvascular fluid filtration in awake newborn lambs after intravenous furosemide. J Clin Invest. 1978; 62(3):601-609
12. Demling RH, Will JA. The effect of furose-mide on the pulmonary transvascular fluid filtration rate. Crit Care Med. 1978;6(5): 317-319
13. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJ. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med. 1973; 288(21):1087-1090
14. Lundergan CF, Fitzpatrick TM, Rose JC, Ramwell PW, Kot PA. Effect of cyclo-oxygenase inhibition on the pulmonary vasodilator response to furosemide. J Pharmacol Exp Ther. 1988;246(1):102-106
15. Almirall JJ, Dolman CS, Eidelman DH. Furosemide-induced bronchodilation in the rat bronchus: evidence of a role for pros-taglandins. Lung. 1997;175(3):155-163
16. Anderson SD, He W, Temple DM. Inhibition by furosemide of inflammatory mediators from lung fragments. N Engl J Med. 1991; 324(2):131
17. Toyoshima K, Momma K, Nakanishi T. In vivo dilatation of the ductus arteriosus induced by furosemide in the rat. Pediatr Res. 2010; 67(2):173-176
18. Green TP, Thompson TR, Johnson D, Lock JE. Furosemide use in premature infants and appearance of patent ductus arteriosus. Am J Dis Child. 1981;135(3):239-243
19. Green TP, Thompson TR, Johnson DE, Lock JE. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. N Engl J Med. 1983;308(13):743-748
20. Atkinson SA, Shah JK, McGee C, Steele BT. Mineral excretion in premature infants receiving various diuretic therapies. J Pediatr. 1988;113(3):540-545
21. Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. J Perinatol. 2000;20(1):41-45
22. Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. J Pediatr. 1989;115(4):615-620
23. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB; DART Study Investigators. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006; 117(1):75-83
24. Hagadorn JI, Sanders MR, Staves C, Herson VC, Daigle K. Diuretics for very low birth weight infants in the first 28 days: a survey of the U.S. neonatologists. J Perinatol. 2011; 31(10):677-681